BACKGROUND: Improving inhaled corticosteroid (ICS) adherence should improve asthma outcomes. OBJECTIVE: In a randomized controlled trial we tested whether an individualized problem-solving (PS) intervention improves ICS adherence and asthma outcomes. METHODS:Adults with moderate or severe asthma from clinics serving urban neighborhoods were randomized to PS (ie, defining specific barriers to adherence, proposing/weighing solutions, trying the best, assessing, and revising) or standard asthma education (AE) for 3 months and then observed for 3 months. Adherence was monitored electronically. Outcomes included the following: asthma control, FEV(1), asthma-related quality of life, emergency department (ED) visits, and hospitalizations. In an intention-to-treat-analysis longitudinal models using random effects and regression were used. RESULTS:Three hundred thirty-three adults were randomized: 49 ± 14 years of age, 72% female, 68% African American, 7% Latino, mean FEV(1) of 66% ± 19%, and 103 (31%) with hospitalizations and 172 (52%) with ED visits for asthma in the prior year. There was no difference between groups in overall change in any outcome (P > .20). Mean adherence (61% ± 27%) decreased significantly (P = .0004) over time by 14% and 10% in the AE and PS groups, respectively. Asthma control improved overall by 15% (P = .002). In both groups FEV(1) and quality of life improved by 6% (P = .01) and 18% (P < .0001), respectively. However, the improvement in FEV(1) only occurred during monitoring but not subsequently after randomization. Rates of ED visits and hospitalizations did not significantly decrease over the study period. CONCLUSION: PS was not better than AE in improving adherence or asthma outcomes. However, monitoring ICS use with provision of medications and attention, which was imposed on both groups, was associated with improvement in FEV(1) and asthma control.
RCT Entities:
BACKGROUND: Improving inhaled corticosteroid (ICS) adherence should improve asthma outcomes. OBJECTIVE: In a randomized controlled trial we tested whether an individualized problem-solving (PS) intervention improves ICS adherence and asthma outcomes. METHODS: Adults with moderate or severe asthma from clinics serving urban neighborhoods were randomized to PS (ie, defining specific barriers to adherence, proposing/weighing solutions, trying the best, assessing, and revising) or standard asthma education (AE) for 3 months and then observed for 3 months. Adherence was monitored electronically. Outcomes included the following: asthma control, FEV(1), asthma-related quality of life, emergency department (ED) visits, and hospitalizations. In an intention-to-treat-analysis longitudinal models using random effects and regression were used. RESULTS: Three hundred thirty-three adults were randomized: 49 ± 14 years of age, 72% female, 68% African American, 7% Latino, mean FEV(1) of 66% ± 19%, and 103 (31%) with hospitalizations and 172 (52%) with ED visits for asthma in the prior year. There was no difference between groups in overall change in any outcome (P > .20). Mean adherence (61% ± 27%) decreased significantly (P = .0004) over time by 14% and 10% in the AE and PS groups, respectively. Asthma control improved overall by 15% (P = .002). In both groups FEV(1) and quality of life improved by 6% (P = .01) and 18% (P < .0001), respectively. However, the improvement in FEV(1) only occurred during monitoring but not subsequently after randomization. Rates of ED visits and hospitalizations did not significantly decrease over the study period. CONCLUSION: PS was not better than AE in improving adherence or asthma outcomes. However, monitoring ICS use with provision of medications and attention, which was imposed on both groups, was associated with improvement in FEV(1) and asthma control.
Authors: S L Spector; R Kinsman; H Mawhinney; S C Siegel; G S Rachelefsky; R M Katz; A S Rohr Journal: J Allergy Clin Immunol Date: 1986-01 Impact factor: 10.793
Authors: Maureen George; Tovia G Freedman; A Lorraine Norfleet; Harold I Feldman; Andrea J Apter Journal: J Allergy Clin Immunol Date: 2003-05 Impact factor: 10.793
Authors: Tracy A Lieu; Jonathan A Finkelstein; Paula Lozano; Angela M Capra; Felicia W Chi; Nancy Jensvold; Charles P Quesenberry; Harold J Farber Journal: Pediatrics Date: 2004-07 Impact factor: 7.124
Authors: Joyce T Bromberger; Sioban Harlow; Nancy Avis; Howard M Kravitz; Adriana Cordal Journal: Am J Public Health Date: 2004-08 Impact factor: 9.308
Authors: Juan Carlos Cardet; Paula J Busse; Jennifer K Carroll; Thomas B Casale; Tamera Coyne-Beasley; Sherrie Dixon-Williams; Maureen Fagan; Victoria E Forth; Anne L Fuhlbrigge; Michelle L Hernandez; David Kaelber; Barbara Kaplan; Margarita Lorenzi; Suzanne Madison; Nancy E Maher; Karen Majewski; Brian Manning; Melissa D McKee; Sylvette Nazario; Wilson D Pace; Michael J Pencina; Cynthia S Rand; Jacqueline Rodriguez-Louis; Lilin She; Joel Shields; Jessica E Teng; Michael E Wechsler; Juan P Wisnivesky; Barbara P Yawn; Elliot Israel Journal: Ann Allergy Asthma Immunol Date: 2020-01-08 Impact factor: 6.347
Authors: Andrea J Apter; Fei Wan; Susan Reisine; Daniel K Bogen; Cynthia Rand; Bruce Bender; Ian M Bennett; Rodalyn Gonzalez; Chantel Priolo; Seema S Sonnad; Tyra Bryant-Stephens; Monica Ferguson; Rhonda C Boyd; Thomas Ten Have; Jason Roy Journal: J Asthma Date: 2013-07-17 Impact factor: 2.515
Authors: Robby Nieuwlaat; Nancy Wilczynski; Tamara Navarro; Nicholas Hobson; Rebecca Jeffery; Arun Keepanasseril; Thomas Agoritsas; Niraj Mistry; Alfonso Iorio; Susan Jack; Bhairavi Sivaramalingam; Emma Iserman; Reem A Mustafa; Dawn Jedraszewski; Chris Cotoi; R Brian Haynes Journal: Cochrane Database Syst Rev Date: 2014-11-20
Authors: Andrea J Apter; Fei Wan; Susan Reisine; Bruce Bender; Cynthia Rand; Daniel K Bogen; Ian M Bennett; Tyra Bryant-Stephens; Jason Roy; Rodalyn Gonzalez; Chantel Priolo; Thomas Ten Have; Knashawn H Morales Journal: J Allergy Clin Immunol Date: 2013-04-13 Impact factor: 10.793
Authors: Milou van Heuckelum; Cornelia H M van den Ende; Anne E J Houterman; Charlotte P M Heemskerk; Sandra van Dulmen; Bart J F van den Bemt Journal: PLoS One Date: 2017-10-09 Impact factor: 3.240